Page 7 - Remunity Pump News Today

United Therapeutics (NASDAQ:UTHR – Free Report) had its price objective raised by LADENBURG THALM/SH SH from $256.00 to $268.00 in a report released on Thursday morning, MarketBeat reports. They currently have a buy rating on the biotechnology company’s stock. Several other brokerages have also weighed in on UTHR. Argus cut their price target on United […]

United Therapeutics (NASDAQ:UTHR – Free Report) had its price target hoisted by Wedbush from $305.00 to $307.00 in a report published on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. A number of other analysts have also commented on UTHR. Argus cut their price objective on shares […]

United Therapeutics (NASDAQ:UTHR – Free Report) had its price target boosted by LADENBURG THALM/SH SH from $256.00 to $268.00 in a research report released on Thursday morning, MarketBeat Ratings reports. LADENBURG THALM/SH SH currently has a buy rating on the biotechnology company’s stock. Several other analysts have also recently commented on the stock. Morgan Stanley […]

United Therapeutics (NASDAQ:UTHR – Free Report) had its price objective upped by LADENBURG THALM/SH SH from $256.00 to $268.00 in a research note published on Thursday morning, MarketBeat Ratings reports. They currently have a buy rating on the biotechnology company’s stock. UTHR has been the subject of a number of other reports. Morgan Stanley decreased […]

Assetmark Inc. grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 12.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 270,423 shares of the biotechnology company’s stock after acquiring an additional 30,060 shares during the period. Assetmark Inc.’s holdings in United Therapeutics […]

Assetmark Inc. grew its position in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 12.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 270,423 shares of the biotechnology company’s stock after acquiring an additional 30,060 shares during the period. Assetmark Inc. owned […]

United Therapeutics (NASDAQ:UTHR – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $5.24 earnings per share for the quarter, topping analysts’ consensus estimates of $4.57 by $0.67, MarketWatch Earnings reports. United Therapeutics had a return on equity of 18.05% and a net margin of 41.29%. The firm had revenue […]

Presentation Operator MessageOperator Good morning, and welcome to the United Therapeutics Corporation Second Quarter 2023 Earnings Webcast. My name is Danielle, and I will be your conference operator...

Premier Fund Managers Ltd reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 12.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,000 shares of the biotechnology company’s stock after selling 3,000 shares during the […]

Shares of United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 12 […]